BI-1808 is under clinical development by BioInvent International and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BI-1808’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BI-1808 overview
BI-1808 is under development for the treatment of non-small cell lung cancer, solid tumor, ovarian cancer and cutaneous T-cell lymphoma (CTCL) including sezary syndrome and mycosis fungoides, fallopian tube cancer,triple-negetive breast cancer, melanoma, TCL/CTCL and peritoneal cancer. The drug candidate is developed based on n-CoDeR antibody library and F.I.R.S.T. technology platform. It acts by targeting alpha tumor necrosis factor receptor 2 (TNFRSF1B).
BioInvent International overview
BioInvent International (BioInvent) is a biotechnology company. It discovers and develops antibody-based therapies for cancer treatment using its proprietary F.I.R.S.T technology platform to identify therapeutic targets and corresponding antibodies. The company’s lead candidate, BI-1808, targets solid tumors and is in a Phase 1/2a trial, both as a standalone therapy and with pembrolizumab. BI-1206 aims to enhance the efficacy of treatments for non-Hodgkin lymphoma by blocking the Fc?RIIB receptor and is supported by a clinical agreement with AstraZeneca. BI-1607, engineered for reduced Fc binding, is set for a Phase 2 study in metastatic melanoma. It is also collaborating with Transgene on BT-001, an oncolytic virus in a Phase 1/2a study. BioInvent is headquartered in Lund, Sweden.
For a complete picture of BI-1808’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
